Research programme: glucokinase stimulants - NovartisAlternative Names: Glucokinase activators - Novartis
Latest Information Update: 16 Jul 2016
At a glance
- Originator Novartis
- Class Sulfonamides
- Mechanism of Action Glucokinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 26 Aug 2010 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)